Spago Nanomedical AB
The answer first
Does Spago Nanomedical beat the market?
No, Spago Nanomedical has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 14% of Nordic stocks
- Quality73
- Value9
- Trend11
No. 151 of 195 in healthcare
Max for seven days
Follow Spago Nanomedical with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Spago Nanomedical
Your first answer is free, no account needed.
Do you own Spago Nanomedical, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Spago Nanomedical and a few more. Free, no card.
Super Stock+44.6%In short
- Spago Nanomedical has fallen 62.1% over the past year, including dividends.
- Overall, Spago Nanomedical ranks better than 14% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 97.3%. The price is 99.8% below its peak now.
What do analysts think of Spago Nanomedical?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 14% of Nordic stocks.
No. 151 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 78 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.25
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−97.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 138 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.3
- P/SPrice divided by sales577.9
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 152 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−63.5%
- 6 months−68.0%
- 9 months−64.9%
- 12 months−62.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Spago Nanomedical
Spago Nanomedical AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 7 employees.
Spago Nanomedical AB (publ), a nanomedicine company, engages in the development projects based on a platform of polymeric materials for diagnosis and treatment of life-threatening and debilitating diseases in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment of liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of cancer. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.


See the full analysis of Spago Nanomedical.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card